February 2025 Trump Tariff Warning
Hours before February 1, 2025, approached, the media reported a delay in U.S. tariffs against Mexico and Canada, to March 1. Unfortunately, the White House confirmed President Trump would proceed with the 25% tariff. Instead of a 60% tariff on China, the U.S. would slap 10% on its imports. The tariffs would have an impact on over $2.1 trillion worth of trade annually. The President cited a Feb. 1 deadline to halt fentanyl and other dangerous chemical ingredients from entering the U.S.Trump softened tariffs on Canadian oil from 25% to 10%. Investors may bet on minimal disruption for Canadian oil firms. The companies include Enbridge (ENB), Suncor (SU), and Cenovus Energy (CVE).Consumers will end up paying for most of the duties. This will add to U.S. inflation rates. Last week, the Federal Reserve halted its interest rate-cutting policy. Although Fed Chair Powell did not cite tariffs, he pointed out that current inflation rates are still higher than the 2.0% target rate.Avoid Automotive StocksAhead of the tariff warnings, investors avoided American automotive stocks. Ford Motor (F) fell below $10.00 last week, while General Motors (GM) fell by even more. GM posted earnings that included restructuring from its business in China. Its guidance also excluded the impact of tariffs.Investors bought Honda (HMC) and Toyota Motor (TM) stock instead.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


